Donald J. Vander Griend, Ph.D. - 2009 Young Investigator Award
Function of the Stem Cell Marker CD133 in the Progression of Castrate-resistant Prostate Cancer
Awarded a $75,000 2009 Young Investigator Award
There is a growing paradigm demonstrating that cancer lethality is the result of the hierarchical expansion of "cancer stem cells" which function as stem-like cells to maintain malignant growth. In prostate cancer, such cancer stem cells are thought to contribute to cancer relapse after hormone therapy. The stem cell marker CD133 has been documented to mark prostate cancer stem cells, but little is known regarding its function and clinical relevance in prostate cancers. The aim of this proposal is to address whether CD133 is a viable target for the development of new methods to predict prostate cancer recurrence as well as new therapies to treat prostate cancers.
"I owe a great deal to the Cancer Research Foundation for giving me a head start. This financial help made the difference between my getting a fast and successful start, and my other wise struggling to obtain the necessary funds to get my research program started."Elaine Fuchs, Ph.D.
Professor, Departments of Medicine and Molecular Genetics and Cell Biology and Human Genetics University of Chicago
April 30, 2010